Table 2.
Demographic and clinical characteristic comparisons between non- or weak responders and responders to the third SARS-CoV-2 mRNA vaccine dose.
| Variable | Total n = 153 | Non- or Weak Responders (<150 U/mL) n = 23 (15%) | Responders (≥150 U/mL) n = 130 (85%) | p-Value | Odds Ratio 1 (95% Confidence Interval) |
|---|---|---|---|---|---|
| Age > 75 years | 74 (48.4%) | 12 (52.2%) | 62 (47.7%) | 0.69 | 1.2 (0.49–2.9) |
| Male sex | 83 (54.2% | 12 (52.2%) | 71 (54.6%) | 0.83 | 1.1 (0.45–2.68) |
| Dialysis vintage (over the 50th percentile) |
75 (49%) | 13 (56.5%) | 62 (47.7%) | 0.44 | 1.43 (0.58–3.48) |
| BNT162b2 vaccine | 71 (46.4%) | 16 (69.6%) | 55 (42.3%) | 0.02 | 3.12 (1.2–8.1) |
| Overweight | 45 (29.4%) | 7 (30.4%) | 38 (29.2%) | 0.97 | 1.06 (0.4–2.7) |
| Obesity | 27 (17.6%) | 3 (13%) | 24 (18.5%) | 0.53 | 0.66 (0.18–2.4) |
| Diabetes | 55 (36.2%) | 7 (30.4%) | 48 (37.2%) | 0.53 | 0.74 (0.28–1.92) |
| Immunosuppressive therapy | 11 (7.2%) | 5 (21.7%) | 6 (4.6%) | 0.01 | 5.74 (1.59–20.83) |
| Active cancer | 5 (3.3%) | 3 (13%) | 2 (1.6%) | 0.03 | 9.52 (1.5–58.82) |
| HIV chronic infection | 4 (2.6%) | 1 (4.3%) | 3 (2.3%) | 0.49 | 1.9 (0.19–19.23) |
| HBV chronic infection | 6 (3.9%) | 1 (4.3%) | 5 (3.9%) | 1 | 1.13 (0.13–10.1) |
| Previous SARS-CoV-2 infection | 20 (13.1%) | 1 (4.3%) | 19 (14.6%) | 0.18 | 3.77 (0.48–29.6) |
1 Odds ratios are calculated to indicate the risk estimate to become non- or weak responder.